|
|
|
European Pharmaceutical Contractor
|
Clinical development accounts for 60 to 70 per cent of the time needed to get a new chemical entity (NCE) to market and over the years, conscientious clinical teams have done all they can to reduce the risk of study delays and to minimise the impact of any setbacks. And indeed there have been considerable successes along the way. Since the 1980s, pharma companies have been able to complement their own resources by calling upon contract research organisations (CROs) to avoid delays caused by lack of resources or inexperience in a particular therapeutic area. More recently, technology and centralised dispatch systems have been used to ensure the timely, reliable distribution of clinical trial supplies to sites actively recruiting patients, while electronic data capture offers the potential to speed up data management and create a real-time study database.
Delay, What Delay?
As each source of delay is identified and overcome, it is hard to ignore the fact that many studies in Western Europe are delayed by poor patient recruitment. Most professionals involved in clinical trials will have experienced this problem first-hand and the published evidence for it is growing. Last year, the British Medical Journal reported that Britain has a poor patient recruitment record, achieving less than 80 per cent of the patients promised (1).
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
Paediatric Clinical Trials
21-22 March 2012, Copthorne Tara Hotel, London, United Kingdom
Designing accurate and safe paediatric formulations is one of the topics being discussed at SMi’s Paediatric Clinical Trials held on 21st & 22nd March 2012
More info >> |
|
 |
News and Press Releases |
 |
The Marketing Machine Helps International Pharma Client with Ambitious Literacy Drug Packaging Rebrand
Full-service advertising and branding firm The Marketing Machine recently finished an ambitious, innovative rebranding project for Danadams Pharmaceuticals Industry Limited to help overcome literacy and distribution challenges with patients in Ghana, South Africa. The firm utilized its award-winning design services team to redesign all of Danadams branding and packaging using intuitive visual icons and color elements to indicate the type of drugs and dosages and better display information more clearly and legibly. Danadams Pharmaceuticals is currently the only manufacturer of anti-retroviral drugs in West Africa. It also manufactures and sells anti-malarials, antibiotics, analgesics and other opportunistic infection drugs for the West African market.
More info >> |
|
|
